Fabry disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

  NCT05206773· Sanofi· Source

• Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

  NCT06052800· Sanofi· Source

• A Study of Replagal in Children and Adults With Fabry Disease in India

  NCT05067868· Shire· Source

• A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

  NCT05280548· Sanofi· Source

• Early Detection of Fabry Disease

  NCT05106764· Takeda· Source

• A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

  NCT07187440· Takeda· Source

• A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

  NCT06019728· Sanofi· Source

• A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

  NCT04974749· Takeda· Source

• Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)

  NCT05671770· Sanofi· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Magnetic Resonance Imaging 1

See which targets of this disease your abstract mentions, and go to the people working on them.